Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CHRM3 antisense RNA 1 (CHRM3-AS1) is a long non-coding RNA (lncRNA) gene found in humans and classified as an antisense RNA because it is transcribed from the DNA strand opposite the CHRM3 gene locus[7][9][14]. Antisense RNAs typically function by regulating the expression of their corresponding sense gene (in this case, CHRM3, which encodes the muscarinic acetylcholine receptor M3) through mechanisms such as RNA-RNA duplex formation, chromatin modulation, or transcriptional interference[2][16]. CHRM3-AS1 is not a protein or receptor, and there is currently no evidence to support its role as a direct therapeutic target or drug-interacting biomolecule. Limited functional studies exist specifically for CHRM3-AS1, but by analogy to other antisense lncRNAs, it is presumed to participate in local regulation of gene expression, which may contribute to disease processes if dysregulated[2][16]. Currently, databases associate CHRM3-AS1 with the RNA gene class and note a possible link to retinitis pigmentosa, but its precise biological and clinical significance remains to be clarified[7][14].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CHRM3 antisense RNA 1 (CHRM3-AS1).